PropertyValue
?:definition
  • A controlled-release formulation of the 5-hydroxytryptamine 3 (5-HT3) antagonist granisetron, in which granisteron is encapsulated in a biodegradable poly(ortho ester) polymer, with antiemetic activity. Upon subcutaneous administration, APF530 slowly erodes and releases the active ingredient granisetron over a period of approximately 5 days. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-HT3 receptors, resulting in the suppression of nausea and vomiting. Check for \'https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C61567\' active clinical trials using this agent. (\'http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61567\' NCI Thesaurus)
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C1831918_PDQ>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C1831918_PDQ>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all